Ken has supported the launch of more than 20 innovative therapies in China over the past three years, as well as a broad range of pipeline assets going through clinical trials.


Ken is a ZS principal and leads the company’s business in China. Ken has focused on the Chinese healthcare market for over 10 years, where he oversees more than 50 projects annually, covering all stages of product life cycle and therapy areas. He serves clients in multinational and domestic pharmaceutical, biotech and medical technology on a broad range of issues.



Ken’s key areas include opportunity assessments and forecasting for pipeline assets, market access and pricing for pre-launch pricing and preparation for reimbursement, go-to-market strategy and organization design, field force strategy, resourcing and implementation and commercial effectiveness.



Prior experience

Ken has worked in the healthcare industry for 17 years, including six years at ZS London and the past 11 years in China. Previously, Ken worked at an investment bank, focusing on mergers and acquisitions and financing for biotech and medical technology companies.




Ken received an MBA with distinction from the London Business School and an M.A. in pharmacology from the University of Cambridge.